Shuttle Pharmaceuticals (SHPH) Competitors

$0.67 +0.03 (+4.03%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 +0.01 (+1.23%)

As of 07:59 PM Eastern

SHPH vs. MAAQ, GNTA, LEXX, HOOK, and CTXR

Should you buy Shuttle Pharmaceuticals stock or one of its competitors? MarketBeat compares Shuttle Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shuttle Pharmaceuticals include Mana Capital Acquisition (MAAQ), Genenta Science (GNTA), Lexaria Bioscience (LEXX), HOOKIPA Pharma (HOOK), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical products" industry.

How does Shuttle Pharmaceuticals compare to Mana Capital Acquisition?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Shuttle Pharmaceuticals had 3 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 3 mentions for Shuttle Pharmaceuticals and 0 mentions for Mana Capital Acquisition. Shuttle Pharmaceuticals' average media sentiment score of 0.94 beat Mana Capital Acquisition's score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Positive
Mana Capital Acquisition	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$11.84	N/A
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Mana Capital Acquisition's return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-444.90%	-188.81%
Mana Capital Acquisition	N/A	N/A	N/A

Summary

Shuttle Pharmaceuticals beats Mana Capital Acquisition on 4 of the 7 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Genenta Science's return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Shuttle Pharmaceuticals	N/A	-444.90%	-188.81%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Shuttle Pharmaceuticals had 1 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Shuttle Pharmaceuticals and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.44 beat Shuttle Pharmaceuticals' score of 0.94 indicating that Genenta Science is being referred to more favorably in the media.

Company	Overall Sentiment
Genenta Science	Positive
Shuttle Pharmaceuticals	Positive

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genenta Science has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$11.84	N/A

Summary

Genenta Science beats Shuttle Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Shuttle Pharmaceuticals has lower revenue, but higher earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	20.68	-$11.90M	-$0.47	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$11.84	N/A

In the previous week, Shuttle Pharmaceuticals had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 3 mentions for Shuttle Pharmaceuticals and 2 mentions for Lexaria Bioscience. Shuttle Pharmaceuticals' average media sentiment score of 0.94 beat Lexaria Bioscience's score of 0.58 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexaria Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Shuttle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shuttle Pharmaceuticals has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,685.84%. Lexaria Bioscience's return on equity of -206.02% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	-1,685.84%	-206.02%	-162.53%
Shuttle Pharmaceuticals	N/A	-444.90%	-188.81%

Lexaria Bioscience has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Lexaria Bioscience currently has a consensus price target of $1.50, suggesting a potential upside of 153.29%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Lexaria Bioscience is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Lexaria Bioscience beats Shuttle Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to HOOKIPA Pharma?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Shuttle Pharmaceuticals has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-444.90%	-188.81%
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Shuttle Pharmaceuticals has higher earnings, but lower revenue than HOOKIPA Pharma. HOOKIPA Pharma is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$11.84	N/A
HOOKIPA Pharma	$9.35M	1.57	-$43.50M	-$3.54	N/A

In the previous week, Shuttle Pharmaceuticals had 3 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 3 mentions for Shuttle Pharmaceuticals and 0 mentions for HOOKIPA Pharma. Shuttle Pharmaceuticals' average media sentiment score of 0.94 beat HOOKIPA Pharma's score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Positive
HOOKIPA Pharma	Neutral

Shuttle Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, HOOKIPA Pharma has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Summary

Shuttle Pharmaceuticals beats HOOKIPA Pharma on 7 of the 13 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Citius Pharmaceuticals?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Citius Pharmaceuticals' return on equity of -49.34% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-444.90%	-188.81%
Citius Pharmaceuticals	N/A	-49.34%	-28.64%

Citius Pharmaceuticals has a consensus price target of $6.00, suggesting a potential upside of 756.65%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$11.84	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.45	N/A

In the previous week, Citius Pharmaceuticals had 3 more articles in the media than Shuttle Pharmaceuticals. MarketBeat recorded 6 mentions for Citius Pharmaceuticals and 3 mentions for Shuttle Pharmaceuticals. Shuttle Pharmaceuticals' average media sentiment score of 0.94 beat Citius Pharmaceuticals' score of 0.93 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shuttle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shuttle Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Summary

Citius Pharmaceuticals beats Shuttle Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get Shuttle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SHPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SHPH vs. The Competition

Export

Metric	Shuttle Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.58M	$3.06B	$6.34B	$12.47B
Dividend Yield	N/A	1.96%	2.80%	5.28%
P/E Ratio	-0.06	12.16	17.27	22.75
Price / Sales	N/A	289.98	547.04	77.06
Price / Cash	N/A	57.86	43.04	56.01
Price / Book	0.60	4.33	9.83	6.91
Net Income	-$11.72M	$72.19M	$3.56B	$333.88M
7 Day Performance	-3.40%	-2.92%	0.27%	0.01%
1 Month Performance	-28.01%	-3.12%	-0.98%	1.75%
1 Year Performance	-88.01%	40.55%	36.22%	32.67%

Shuttle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SHPH Shuttle Pharmaceuticals	0.9687 of 5 stars	$0.67 +4.0%	N/A	-89.0%	$3.58M	N/A	N/A	5	News Coverage Earnings Report Gap Up
MAAQ Mana Capital Acquisition	N/A	$1.82 -1.6%	N/A	-66.5%	$14.79M	N/A	N/A	1	Gap Up
GNTA Genenta Science	1.3113 of 5 stars	$0.63 +2.0%	N/A	-85.3%	$14.74M	N/A	N/A	7	Positive News Short Interest Decrease Gap Up
LEXX Lexaria Bioscience	3.0669 of 5 stars	$0.60 +4.2%	$1.50 +149.6%	-42.4%	$14.63M	$710K	N/A	7
HOOK HOOKIPA Pharma	N/A	$1.18 flat	N/A	-16.3%	$14.55M	$9.35M	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SHPH) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shuttle Pharmaceuticals (SHPH) Competitors

SHPH vs. MAAQ, GNTA, LEXX, HOOK, and CTXR

How does Shuttle Pharmaceuticals compare to Mana Capital Acquisition?

Summary

How does Shuttle Pharmaceuticals compare to Genenta Science?

Summary

How does Shuttle Pharmaceuticals compare to Lexaria Bioscience?

Summary

How does Shuttle Pharmaceuticals compare to HOOKIPA Pharma?

Summary

How does Shuttle Pharmaceuticals compare to Citius Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHPH vs. The Competition

Shuttle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shuttle Pharmaceuticals (SHPH) Competitors

SHPH vs. MAAQ, GNTA, LEXX, HOOK, and CTXR

How does Shuttle Pharmaceuticals compare to Mana Capital Acquisition?

Do insiders and institutionals believe in SHPH or MAAQ?

Does the media prefer SHPH or MAAQ?

Which has preferable valuation and earnings, SHPH or MAAQ?

Do analysts rate SHPH or MAAQ?

Is SHPH or MAAQ more profitable?

Summary

How does Shuttle Pharmaceuticals compare to Genenta Science?

Is GNTA or SHPH more profitable?

Do analysts rate GNTA or SHPH?

Does the media refer more to GNTA or SHPH?

Do institutionals and insiders believe in GNTA or SHPH?

Which has more risk and volatility, GNTA or SHPH?

Which has preferable valuation and earnings, GNTA or SHPH?

Summary

How does Shuttle Pharmaceuticals compare to Lexaria Bioscience?

Which has higher earnings & valuation, LEXX or SHPH?

Does the media prefer LEXX or SHPH?

Is LEXX or SHPH more profitable?

Which has more risk and volatility, LEXX or SHPH?

Do analysts prefer LEXX or SHPH?

Do institutionals & insiders have more ownership in LEXX or SHPH?

Summary

How does Shuttle Pharmaceuticals compare to HOOKIPA Pharma?

Is SHPH or HOOK more profitable?

Do analysts rate SHPH or HOOK?

Do institutionals & insiders have more ownership in SHPH or HOOK?

Which has better earnings and valuation, SHPH or HOOK?

Does the media favor SHPH or HOOK?

Which has more volatility & risk, SHPH or HOOK?

Summary

How does Shuttle Pharmaceuticals compare to Citius Pharmaceuticals?

Is SHPH or CTXR more profitable?

Do analysts rate SHPH or CTXR?

Do institutionals & insiders have more ownership in SHPH or CTXR?

Which has better earnings and valuation, SHPH or CTXR?

Does the media favor SHPH or CTXR?

Which has more volatility & risk, SHPH or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHPH vs. The Competition

Shuttle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools